SCYX

Over the past six months, SCYNEXIS's stock has been influenced by several events. In March 2026, the company announced a $40.0 million private placement and completed the acquisition of PXL-770. The full-year 2025 financial results were reported, including the receipt of $24.8 million from GSK in Q4 2025 and recognition of $17.2 million in license agreement revenue. SCY-247 advanced in clinical trials, receiving FDA QIDP and Fast Track Designations. In November 2025, Q3 financial results were reported, and the company announced it would receive $24.8 million from GSK related to the Phase 3 MARIO study. Shareholders experienced dilution with a 104% increase in shares outstanding. The stock price has fluctuated between $0.565 and $1.31, and as of May 8, 2026, it was trading around $0.916, marking a 53.95% increase over the past six months.